The Alabama Supreme Court recently upheld its decision in Wyeth v. Weeks, holding that brand-name drug manufacturers can be held liable for injuries caused by their generic counterparts. The... Read more
The total amount of money our citizens spend on prescription drugs each year has been rising in the last decade. Similarly, in most states, Medicaid agencies are seeing an increasing amount... Read more
On March 27, 2014, the New York Times published an editorial in support of a proposed change to the U.S. Food and Drug Administration’s (FDA) rules governing labeling of generic drugs. The e... Read more
We wrote last month about how big business has fared extremely well in cases decided by the U.S. Supreme Court. Business Week recently complied a listing of five important pro-business decis... Read more
Bayer has agreed to a $74 million settlement in a case where Plaintiffs alleged the drug maker violated antitrust laws by participating in pay-for-delay activities surrounding its drug Cipro... Read more
The U.S. Supreme Court gave pharmaceutical companies another huge gift on June 25th, largely shielding the generic industry from lawsuits for the design of their drugs. This is the second Su... Read more
Two years ago, the Supreme Court limited the conditions under which consumers of generic drugs could sue the manufacturers. In the case, Pliva v. Mensing the Court said the generic company d... Read more
Many of us were somewhat surprised when in 2009 the United States Supreme Court upheld the jury’s determination in Wyeth v. Levine. In the Levine case, the Court determined that the Hatch-Wa... Read more
In Ciprofloxacin Hydrochloride Antitrust Litigation, the Second Circuit Court of Appeals recently indicated that it is willing to reexamine its prior case law with respect to “reverse settle... Read more
Given the increases in costs of prescription drugs over the years, it’s not uncommon for doctors, pharmacists and insurers to switch patients to the generic form of prescribed drugs in an ef... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.